Status:
COMPLETED
Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
Lead Sponsor:
National Institute of Cardiology, Warsaw, Poland
Conditions:
Atrial Fibrillation
Hypertrophic Cardiomyopathy
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
Paroxysmal or chronic atrial fibrillation (AF) develops in about 20- 25% of adult patients with hypertrophic cardiomyopathy (HCM) and represents an important complication in the clinical course of the...
Eligibility Criteria
Inclusion
- Patients with hypertrophic cardiomyopathy and paroxysmal or chronic atrial fibrillation
Exclusion
- Severe hear failure (NYHA IV)
- Left ventricular ejection fraction \<0.30
- Left atrial diameter \>65 mm
- Age \> 70 years
- Contraindication to anticoagulation with warfarin
- Presence of a mechanical prosthetic valve
- Presence of left atrial thrombus on TEE or CT
- Woman currently pregnant
- Renal failure (GFR \< 30 ml/min)
- Hepatic failure
- Untreated hypothyroidism or hyperthyroidism
- LVOT gradient \> 50 mmHg
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2012
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00821353
Start Date
January 1 2009
End Date
June 1 2012
Last Update
February 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Cardiology
Warsaw, Poland